Metabolic SyndromeNCT01065753
Multi-faceted Evaluations Following Weight Reduction in Subjects With Metabolic Syndrome
A study testing Lifestyle Counseling in people with Metabolic Syndrome, run by Taichung Veterans General Hospital at 1 site in Taiwan.
Trial summary
Central obesity, core of metabolic syndrome, has been recognized as one of the rooting factors for development of diabetes and cardiovascular disease. Although efforts have been devoted to the studies of central obesity and/or metabolic syndrome, much remained unknown as to how obesity influences cellular as well as… Read more about this study
- Who is it for?
- Ages 20 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Metabolic Syndrome
- What is being tested?
- Lifestyle Counseling
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteTaiwan
- Study dates
- Apr 2008to Feb 2009
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age between 20 and 65 years
- Metabolic syndrome by IDF 2005 criteria
Who cannot join
- known diabetes
- obesity due to endocrinologic disorders
- Psychological disorder or using psychological medications
- Abnormal liver function (three-fold upper normal limit)
- Abnormal renal function (1.5-fold upper normal limit)
- Investigator judgement for abnormal clinical data
Show all 11Show fewer
- Life-threatening disease
- Acute infective status
- Alcohol or drug abuse
- pregnant potency without prevention
- receiving other clinical trial in recently three months
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Study of Wight Reduction by Life-style Modification
Central obesity, core of metabolic syndrome, has been recognized as one of the rooting factors for development of diabetes and cardiovascular disease. Although efforts have been devoted to the studies of central obesity and/or metabolic syndrome, much remained unknown as to how obesity influences cellular as well as cardiac functions, what is the central regulation of one's body weight.
Weight loss is an undisputed way to improve cardiovascular and metabolic disorders in obese individuals. Previous studies have demonstrated that weight loss by 5% of initial weight universally provide substantial benefits in these subjects. However, there are little integrated research teams, composed of different disciplines, share common weight reduction program to look at different aspects of weight reduction in non-diabetic individuals with metabolic syndrome. The significances of this proposal we plan to target, namely Rho kinase activity from peripheral leukocyte, several cardiac functions measured by noninvasive technique (VP-2000) and MRI, circulating brain-derived neurotrophic factors (BDNF) levels, are fully explained detailed in each sub-proposal.
Read more
In order to accomplish this integrated proposal, we will form research teams including endocrinologists, cardiologists, radiologists, and a coordinating data center. We pan to recruit 40 non-diabetic individuals with metabolic syndrome to participate this 12-16 weeks weight reduction program. Twenty-five age, sex matched non-diabetes lean will be served as controls. Oral glucose tolerance test, fasting blood obtained, noninvasive vascular and MRI examinations will be applied before and after weight reduction program in those achieving at least 5% loss of initial weight.
In summary, this study will investigate the effects of weight loss on (1) Rho kinase activity obtained from peripheral leukocyte; (2). Aortic stiffness, central aortic pressure and hemodynamic by a noninvasive vascular profiling system (VP-2000); (3) Brain function specifically reflecting by circulating BDNF; (4). Aortic elastic properties and left ventricular function by using MRI examinations, in non-diabetic individuals of metabolic syndrome.
Read the detailed description
Obesity, in particular central obesity, has been one of the important documented risk factors for development of diabetes and cardiovascular disease. Recent re-delineated various versions of definitions of metabolic syndrome, has fueled further the critical involvement of central adiposity in these disorders through several facets, including many increased circulating pro-inflammatory cytokines, directly or indirectly linking to visceral adipose tissue expressions. Although lots of efforts have been devoted to the studies of central obesity and/or metabolic syndrome, much remained unknown as to how obesity affect cellular as well as cardiac function, what is the central regulation of one's body weight, and how to measure fat in visceral organs precisely.
Weight loss is an undisputed way to improve cardiovascular and metabolic disorders. Both a recent review article and data from us demonstrated that only weight loss by 5% of initial weight universally delivered benefits on obese individuals. However, there is little integrated research teams from different disciplines share common weight reduction protocol and look at different aspects of weight reduction in non-diabetic individuals with metabolic syndrome. The significances of this proposal we plan to target are explained in detail in each sub-proposal. However, we would like to make a briefing description here.
- . Rho kinase (ROCK) is a serine/threonine kinase that mediates the downstream signaling of the small guanosine triphosphate- binding protein, Rho, on the actin cytoskeleton. In mostly animal models, the inhibition of ROCK ameliorates many cardiovascular conditions, including hypertension, atherosclerosis, myocardial fibrosis, and stroke. Recent study from Taiwan showed that ROCK activity is increased in patients with metabolic syndrome.
- . Obese and overweight individuals have increased levels of arterial stiffness which is a measure of aortic and large vessel distensibility or compliance. Weight loss could induce significant reduction in sympathetic activity and blood pressure. However, little is known as whether weight loss can improve arterial stiffness, central aortic blood pressure and related hemodynamics.
- . Brain-derived neurotrophic factor (BDNF), recently reported related to Alzheimer's disease, is present in brain tissues extensively. It is also noted that low circulating level of BDNF was associated with impaired glucose metabolism, and might be associated higher BMI or body fat. We are interesting in effect of weight reduction on circulating BDNF values in non-diabetic subjects with metabolic syndrome.
- . Magnetic resonance imaging (MRI) of the heart is frequently used and can provide accurate and reproducible measurement of LV mass, volumes, systolic function and aortic pulse velocity. Although echo-cardiography has been applied to study effect of weight loss on cardiac function, there has been no study by using cardiac MRI to measure cine images of cardiac function and related variables before and after weight reduction in non-diabetic subjects with metabolic syndrome.
In order to accomplish this integrated proposal, we will formulate research teams including endocrinologists, cardiologists, radiologists, and a data center, coordinated by a PhD researcher (infra-structure as described below). We will recruit 40 non-diabetic individuals with metabolic syndrome (fulfilled the criteria from IDF, 2006 and DOH of Taiwan). Twenty-five age, sex matched non-diabetes lean will be served as controls.
Written informed consent will be obtained from each subject before being enrolled into the study after approval from IRB of Taichung VGH, Taichung, Taiwan. This weight reduction program will be assisted by experienced dieticians and sports experts, all of whom we had collaborated and published article previously. This program will last for 12-16 weeks with every participants join together courses 4 hours per week. Each participant will be introduced a dietary plan based on a caloric reduction of 1200 Kcal/day from the values thought necessary to maintain their usual weight. Subject will be asked to follow dietary advice and their eating habit will be reviewed by dietician at the time of their weekly visit. Activity levels will be encouraged to reach 30 min each day and at least 5 days a week. During each visit, weight of each participant will be recorded and announced. Meals replacement may considered for those did not get much improvement during weekly monitoring since recent report indicated that meals replacement may provide certain help in reducing body weight. We are confident that adequate weight reduction (at least 5% of initial weight) and good compliance will be achieved given our previous experience.
In aggregate, this study will investigate the effects of weight loss on (1) Rho kinase activity obtained from peripheral leukocyte (2). Aortic stiffness, central aortic pressure and hemodynamic by a noninvasive technique (3) Brain function specifically reflecting by circulating BDNF levels (4). Aortic elastic properties and left ventricular function by using MRI examinations, in non-diabetic individuals of metabolic syndrome. Findings from this integrated proposal will provide valuable information as mild to moderate weight loss (5% of initial body weight) in cellular, cardiac and central nervous system in additional to well-known effects on lipids, inflammatory cytokines and insulin resistance in non-diabetic subjects with metabolic syndrome.
Follow up- Subjects received physical check up, fasting blood tests and OGTT 6 and 12 months after the end of study.
- Conditions
- Metabolic Syndrome
- Being tested
- Lifestyle Counseling
- Keywords
- Rho kinase, Brain-derived neurotrophic factor
- Medical subject headings
- Metabolic Syndrome, Hereditary Sensory and Autonomic Neuropathies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lifestyle CounselingBehavioural
Diet control with exercise
| Study group | Role | What they receive |
|---|---|---|
| Life-style modification | Experimental | Life-style modification for 40 study subjects with metabolic syndrome in comparison to 25 non-obesity subjects for control. Receives: Behavioral: Lifestyle Counseling |
What is being measured
The primary outcome is the main question the study is designed to answer.
change of body weight
Measured: 12-16 weeks
Secondary outcomes (5)
Change of Rho kinase
Measured: 12-16 weeks
Change of central aortic blood pressure and related hemodynamics
Measured: 12-16 weeks
Change of Brain-derived neurotrophic factor
Measured: 12-16 weeks
Change of MRI images of cardiac function
Measured: 12-16 weeks
Change of profiles before and after OGTT
Measured: 12-16 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2010 (estimated)
- Study startApr 2008
- Primary completionJan 2009
- Study completionFeb 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Metabolic SyndromeStudies of the same condition, open and under way.
- More trials run by Taichung Veterans General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Taichung Veterans General Hospital
- Sponsor type
- University, hospital or other
- Investigators
- Wayne HH Sheu, MD, PhD, Principal investigator, Taichung Veterans General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01065753
- Sponsor's protocol ID
- C07220
- Status last verified
- Dec 2009
- First submitted
- 8 Feb 2010
- Last updated
- 9 Feb 2010
- Results posted
- No
- Data monitoring committee
- No
Publications
Liang KW, Tsai IC, Lee WJ, Lin SY, Lee WL, Lee IT, Fu CP, Wang JS, Sheu WH. Correlation between reduction of superior interventricular groove epicardial fat thickness and improvement of insulin resistance after weight loss in obese men. Diabetol Metab Syndr. 2014 Oct 29;6(1):115. doi: 10.1186/1758-5996-6-115. eCollection 2014.
PubMed 25383099Lee IT, Fu CP, Lee WJ, Liang KW, Lin SY, Wan CJ, Sheu WH. Brain-derived neurotrophic factor, but not body weight, correlated with a reduction in depression scale scores in men with metabolic syndrome: a prospective weight-reduction study. Diabetol Metab Syndr. 2014 Feb 13;6(1):18. doi: 10.1186/1758-5996-6-18.
PubMed 24524285Lee IT, Lee WJ, Tsai IC, Liang KW, Lin SY, Wan CJ, Fu CP, Sheu WH. Brain-derived neurotrophic factor not associated with metabolic syndrome but inversely correlated with vascular cell adhesion molecule-1 in men without diabetes. Clin Chim Acta. 2012 May 18;413(9-10):944-8. doi: 10.1016/j.cca.2012.02.013. Epub 2012 Feb 21.
PubMed 22374129
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Wight Reduction by Life-style Modification
- ClinicalTrials.gov ID
- NCT01065753
- Acronym / sponsor ID
- C07220
- Conditions
- Metabolic Syndrome
- Keywords
- Rho kinase, Brain-derived neurotrophic factor
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Taichung Veterans General HospitalUniversity, hospital or other
- Study start
- Apr 2008
- Primary completion
- Jan 2009 (actual)
- Study completion
- Feb 2009 (actual)
- First posted
- 9 Feb 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Central obesity, core of metabolic syndrome, has been recognized as one of the rooting factors for development of diabetes and cardiovascular disease. Although efforts have been devoted to the studies of central obesity and/or metabolic syndrome, much remained unknown as to how obesity influences cellular as well as cardiac functions, what is the central regulation of one's body weight.
Weight loss is an undisputed way to improve cardiovascular and metabolic disorders in obese individuals. Previous studies have demonstrated that weight loss by 5% of initial weight universally provide substantial benefits in these subjects. However, there are little integrated research teams, composed of different disciplines, share common weight reduction program to look at different aspects of weight reduction in non-diabetic individuals with metabolic syndrome. The significances of this proposal we plan to target, namely Rho kinase activity from peripheral leukocyte, several cardiac functions measured by noninvasive technique (VP-2000) and MRI, circulating brain-derived neurotrophic factors (BDNF) levels, are fully explained detailed in each sub-proposal.
In order to accomplish this integrated proposal, we will form research teams including endocrinologists, cardiologists, radiologists, and a coordinating data center. We pan to recruit 40 non-diabetic individuals with metabolic syndrome to participate this 12-16 weeks weight reduction program. Twenty-five age, sex matched non-diabetes lean will be served as controls. Oral glucose tolerance test, fasting blood obtained, noninvasive vascular and MRI examinations will be applied before and after weight reduction program in those achieving at least 5% loss of initial weight.
In summary, this study will investigate the effects of weight loss on (1) Rho kinase activity obtained from peripheral leukocyte; (2). Aortic stiffness, central aortic pressure and hemodynamic by a noninvasive vascular profiling system (VP-2000); (3) Brain function specifically reflecting by circulating BDNF; (4). Aortic elastic properties and left ventricular function by using MRI examinations, in non-diabetic individuals of metabolic syndrome.
Detailed description
Obesity, in particular central obesity, has been one of the important documented risk factors for development of diabetes and cardiovascular disease. Recent re-delineated various versions of definitions of metabolic syndrome, has fueled further the critical involvement of central adiposity in these disorders through several facets, including many increased circulating pro-inflammatory cytokines, directly or indirectly linking to visceral adipose tissue expressions. Although lots of efforts have been devoted to the studies of central obesity and/or metabolic syndrome, much remained unknown as to how obesity affect cellular as well as cardiac function, what is the central regulation of one's body weight, and how to measure fat in visceral organs precisely.
Weight loss is an undisputed way to improve cardiovascular and metabolic disorders. Both a recent review article and data from us demonstrated that only weight loss by 5% of initial weight universally delivered benefits on obese individuals. However, there is little integrated research teams from different disciplines share common weight reduction protocol and look at different aspects of weight reduction in non-diabetic individuals with metabolic syndrome. The significances of this proposal we plan to target are explained in detail in each sub-proposal. However, we would like to make a briefing description here.
- . Rho kinase (ROCK) is a serine/threonine kinase that mediates the downstream signaling of the small guanosine triphosphate- binding protein, Rho, on the actin cytoskeleton. In mostly animal models, the inhibition of ROCK ameliorates many cardiovascular conditions, including hypertension, atherosclerosis, myocardial fibrosis, and stroke. Recent study from Taiwan showed that ROCK activity is increased in patients with metabolic syndrome.
- . Obese and overweight individuals have increased levels of arterial stiffness which is a measure of aortic and large vessel distensibility or compliance. Weight loss could induce significant reduction in sympathetic activity and blood pressure. However, little is known as whether weight loss can improve arterial stiffness, central aortic blood pressure and related hemodynamics.
- . Brain-derived neurotrophic factor (BDNF), recently reported related to Alzheimer's disease, is present in brain tissues extensively. It is also noted that low circulating level of BDNF was associated with impaired glucose metabolism, and might be associated higher BMI or body fat. We are interesting in effect of weight reduction on circulating BDNF values in non-diabetic subjects with metabolic syndrome.
- . Magnetic resonance imaging (MRI) of the heart is frequently used and can provide accurate and reproducible measurement of LV mass, volumes, systolic function and aortic pulse velocity. Although echo-cardiography has been applied to study effect of weight loss on cardiac function, there has been no study by using cardiac MRI to measure cine images of cardiac function and related variables before and after weight reduction in non-diabetic subjects with metabolic syndrome.
In order to accomplish this integrated proposal, we will formulate research teams including endocrinologists, cardiologists, radiologists, and a data center, coordinated by a PhD researcher (infra-structure as described below). We will recruit 40 non-diabetic individuals with metabolic syndrome (fulfilled the criteria from IDF, 2006 and DOH of Taiwan). Twenty-five age, sex matched non-diabetes lean will be served as controls.
Written informed consent will be obtained from each subject before being enrolled into the study after approval from IRB of Taichung VGH, Taichung, Taiwan. This weight reduction program will be assisted by experienced dieticians and sports experts, all of whom we had collaborated and published article previously. This program will last for 12-16 weeks with every participants join together courses 4 hours per week. Each participant will be introduced a dietary plan based on a caloric reduction of 1200 Kcal/day from the values thought necessary to maintain their usual weight. Subject will be asked to follow dietary advice and their eating habit will be reviewed by dietician at the time of their weekly visit. Activity levels will be encouraged to reach 30 min each day and at least 5 days a week. During each visit, weight of each participant will be recorded and announced. Meals replacement may considered for those did not get much improvement during weekly monitoring since recent report indicated that meals replacement may provide certain help in reducing body weight. We are confident that adequate weight reduction (at least 5% of initial weight) and good compliance will be achieved given our previous experience.
In aggregate, this study will investigate the effects of weight loss on (1) Rho kinase activity obtained from peripheral leukocyte (2). Aortic stiffness, central aortic pressure and hemodynamic by a noninvasive technique (3) Brain function specifically reflecting by circulating BDNF levels (4). Aortic elastic properties and left ventricular function by using MRI examinations, in non-diabetic individuals of metabolic syndrome. Findings from this integrated proposal will provide valuable information as mild to moderate weight loss (5% of initial body weight) in cellular, cardiac and central nervous system in additional to well-known effects on lipids, inflammatory cytokines and insulin resistance in non-diabetic subjects with metabolic syndrome.
Follow up- Subjects received physical check up, fasting blood tests and OGTT 6 and 12 months after the end of study.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Life-style modification | Experimental | Behavioral: Lifestyle CounselingLife-style modification for 40 study subjects with metabolic syndrome in comparison to 25 non-obesity subjects for control. |
Who may qualify
- Ages
- 20 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Age between 20 and 65 years
- Metabolic syndrome by IDF 2005 criteria
Key exclusion criteria (11 listed)
- known diabetes
- obesity due to endocrinologic disorders
- Psychological disorder or using psychological medications
- Abnormal liver function (three-fold upper normal limit)
- Abnormal renal function (1.5-fold upper normal limit)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lifestyle CounselingDiet control with exercise | Behavioural | Life-style modification |
Primary outcome
change of body weight
Time frame: 12-16 weeks
5 secondary outcomes
Change of Rho kinase
Time frame: 12-16 weeks
Change of central aortic blood pressure and related hemodynamics
Time frame: 12-16 weeks
Change of Brain-derived neurotrophic factor
Time frame: 12-16 weeks
Change of MRI images of cardiac function
Time frame: 12-16 weeks
Change of profiles before and after OGTT
Time frame: 12-16 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2010.
- Derived from this study: PubMed 25383099Liang KW, Tsai IC, Lee WJ, Lin SY, Lee WL, Lee IT, Fu CP, Wang JS, Sheu WH. Correlation between reduction of superior interventricular groove epicardial fat thickness and improvement of insulin resistance after weight loss in obese men. Diabetol Metab Syndr. 2014 Oct 29;6(1):115. doi: 10.1186/1758-5996-6-115. eCollection 2014.
- Derived from this study: PubMed 24524285Lee IT, Fu CP, Lee WJ, Liang KW, Lin SY, Wan CJ, Sheu WH. Brain-derived neurotrophic factor, but not body weight, correlated with a reduction in depression scale scores in men with metabolic syndrome: a prospective weight-reduction study. Diabetol Metab Syndr. 2014 Feb 13;6(1):18. doi: 10.1186/1758-5996-6-18.
- Derived from this study: PubMed 22374129Lee IT, Lee WJ, Tsai IC, Liang KW, Lin SY, Wan CJ, Fu CP, Sheu WH. Brain-derived neurotrophic factor not associated with metabolic syndrome but inversely correlated with vascular cell adhesion molecule-1 in men without diabetes. Clin Chim Acta. 2012 May 18;413(9-10):944-8. doi: 10.1016/j.cca.2012.02.013. Epub 2012 Feb 21.
Related trials for Metabolic Syndrome
RecruitingObservational study
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Fanconi Anemia, Inherited Bone Marrow Failure Syndrome
Not yet recruitingPhase 2
Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Mild Autonomous Cortisol Secretion (MACS), Diabetes Mellitus (Type 2)
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
Not yet recruitingPhase 2
Effects of Meal Macronutrients on Postprandial Lipids
Nephrotic Syndrome, Lipodystrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wayne HH Sheu, MD, PhD principal investigator
Taichung Veterans General Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Lifestyle Counseling in people with Metabolic Syndrome, run by Taichung Veterans General Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Feb 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
change of body weight (time frame: 12-16 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01065753, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2010.